Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018;137(2):109-118.
Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165-182.
Kirkland EB, Heincelman M, Bishu KG, et al. Trends in healthcare expenditures among US adults with hypertension: national estimates, 2003–2014. J Am Heart Assoc. 2018;7(11):e008731.
Wilson PWF, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867-1872.
Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med. 2002;162(5):569-574.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
Wang NY, Hunter Young J, Meoni LA, et al. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins precursors study. Arch Intern Med. 2008;168(6):643-648.
Centers for Disease Control and Prevention. Impact of racism on our nation’s health. April 8,2021. Accessed October 24, 2022. https://www.cdc.gov/minorityhealth/racism-disparities/impact-of-racism.html
Zhou D, Xi B, Zhao M, et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III linked mortality study. Sci Rep. 2018;8(1):9418.
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in JAMA. 2014; 311(17): 1809]. JAMA. 2014;311(5):507-520.
Qaseem A, Wilt TJ, Rich R, et al.; Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians [published correction appears in Ann Intern Med. 2018; 168(7): 530–532]. Ann Intern Med. 2017;166(6):430-437.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published corrections appear in Hypertension. 2018; 71(6): e136–e139, and Hypertension. 2018; 72(3): e33]. Hypertension. 2018;71(6):1269-1324.
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. March 18, 2022. Accessed October 24, 2022. https://www.nice.org.uk/guidance/ng136
Stergiou GS, Palatini P, Parati G, et al.; European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302.
Tschanz MP, Cushman WC, Harrell TE, et al. Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense clinical practice guideline: the diagnosis and management of hypertension in the primary care setting. Ann Intern Med. 2020;173(11):904-913.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018; 71(6): e140–e144]. Hypertension. 2018;71(6):e13-e115.
American Academy of Family Physicians. Guidelines developed by external organizations not endorsed by the AAFP. Accessed November 10, 2021. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/non-endorsed.html
Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020(12):CD004349.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis [published correction appears in Lancet. 2021; 397(10288): 1884]. Lancet. 2021;397(10285):1625-1636.
Zhang W, Zhang S, Deng Y, et al.; STEP Study Group. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385(14):1268-1279.
Dallaire-Théroux C, Quesnel-Olivo MH, Brochu K, et al. Evaluation of intensive vs standard blood pressure reduction and association with cognitive decline and dementia: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(11):e2134553.
Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2020(9):CD010315.
American Academy of Family Physicians. Clinical Practice Guideline Manual. December 2017. Accessed November 10, 2021. http://www.aafp.org/family-physician/patient-care/clinical-recommendations/cpg-manual.html
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406.
Guyatt GH, Oxman AD, Kunz R, et al.; GRADE Working Group. What is “quality of evidence” and why is it important to clinicians?. BMJ. 2008;336(7651):995-998.
Guyatt GH, Schünemann HJ, Djulbegovic B, et al. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015;68(5):597-600.
Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
Wright JT, Williamson JD, Whelton PK, et al.; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control [published correction appears in N Engl J Med. 2017; 377(25): 2506]. N Engl J Med. 2015;373(22):2103-2116.
Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002;13(7):1733-1739.
Parkash R, Wells GA, Sapp JL, et al. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). Circulation. 2017;135(19):1788-1798.
Benavente OR, Coffey CS, Conwit R, et al.; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial [published correction appears in Lancet. 2013; 382(9891): 506]. Lancet. 2013;382(9891):507-515.
- Verdecchia P, Staessen JA, Angeli F, et al.; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial [published correction appears in Lancet. 2009; 372(9693): 880]. Lancet. 2009;374(9689):525-533.
Mant J, McManus RJ, Roalfe A, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke–Blood Pressure) randomised controlled trial. BMJ. 2016;352:i708.
Toto RD, Mitchell HC, Smith RD, et al. “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995;48(3):851-859.
Ruggenenti P, Perna A, Loriga G, et al.; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939-946.
Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351(9118):1755-1762.
Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64.
Lewis CE, Fine LJ, Beddhu S, et al.; SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384(20):1921-1930.
Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force recommendation statement. JAMA. 2020;324(20):2069-2075.
Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73(5):e35-e66.
Westby A, Okah E, Ricco J. Race-based treatment decisions perpetuate structural racism. Am Fam Physician. 2020;102(3):136-137.
Hoffman KM, Trawalter S, Axt JR, et al. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci U S A. 2016;113(16):4296-4301.
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-1357.